Ofer Gonen - 11 Nov 2026 Form 4 Insider Report for MediWound Ltd. (MDWD)

Reporting relationship: Chief Executive Officer
Issuer ticker: MDWD
Reported as of: 11 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Nov 2026, 07:38:22 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Yaron Meyer, attorney-in-fact

Filing notes and source

Key filing fact

Ofer Gonen filed Form 4 for MediWound Ltd. (MDWD) on 12 Nov 2026.

Key facts

This page summarizes Ofer Gonen's Form 4 filing for MediWound Ltd. (MDWD).
2 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 12 Nov 2026, 07:38.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796468 Primary reporting owner

Gonen Ofer

Relationship: Chief Executive Officer
Address: C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL
Signature: /s/ Yaron Meyer, attorney-in-fact
Signature date: 12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDWD transaction

Ordinary Shares

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +8,168
Change %: +14%
Price: $13.48^*
Shares after: 66,019
Date: 11 Nov 2026
Ownership: Direct
Footnotes: F1

MDWD holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,784
Date: 11 Nov 2026
Ownership: Direct
Footnotes: F2, F5

MDWD holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,500
Date: 11 Nov 2026
Ownership: Direct
Footnotes: F3, F5

MDWD holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,900
Date: 11 Nov 2026
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDWD transaction Derivative

Series A Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: -8,168
Change %: -100%
Price
Shares after: 0
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,168
Exercise price: $13.48
Footnotes: F1

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 85,714
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 85,714
Exercise price: $13.14
Footnotes: F5, F6

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 86,000
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 86,000
Exercise price: $11.88
Footnotes: F5, F7

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 94,273
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 94,273
Exercise price: $12.73
Footnotes: F5, F8

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 68,000
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 68,000
Exercise price: $18.54
Footnotes: F5, F9

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 71,000
Date: 11 Nov 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 71,000
Exercise price: $17.60
Footnotes: F5, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

On November 10, 2026, the Reporting Person exercised Series A Warrants to purchase 8,168 ordinary shares at an exercise price of $13.475 per share, paying the aggregate exercise price in cash. The Reporting Person did not sell any of the ordinary shares acquired upon the exercise. No separate price was paid for the Series A Warrants upon exercise. The exercise price is reported in column 2 and in Table I. The amount reported in Column 5 also includes 35,714 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and became fully vested on June 7, 2026.

Footnote F2

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F3

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F4

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vest upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F5

There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Footnote F6

The options reported in this row were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F7

The options reported in this row were granted to the Reporting Person on May 31, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F8

The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F9

The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F10

The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vest upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

SEC remarks

Exhibit 24.1 - Power of Attorney